Abstract
Background: The optimal duration of treatment for metastatic patients who achieve a complete response with immune checkpoint inhibitors is unknown. Methods: The outcome for sixmetastatic bladder cancer patients who received short course of pembrolizumab is reported. Results: A median number of sevencycles of pembrolizumab was given. After a median follow-up of 38months, progressive disease was confirmed in three patients. All patients relapsed in lymph nodes and underwent pembrolizumab rechallenge: oneachieved a complete response, another a partial response. Conclusion: Our case series paves the way for discontinuation of pembrolizumab in patients who achieve a complete response since threeout of six patients remain free of disease after 3-year follow-up. Prospective studies are required to confirm our results.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
